时间：2021-02-03 14:07:50来源： 德国新闻网
A Shenzhen-based drugmaker on Tuesday began trial production of a COVID-19 vaccine from multinational pharmaceutical company AstraZeneca.
Shenzhen Kangtai Biological Products Co. Ltd. announced that it has built a production workshop for the adenovirus vector vaccine developed by AstraZeneca and the University of Oxford, which won the approval for emergency use in the United Kingdom on Dec. 30.
The facility, with a floor area of 2,200 square meters, has an annual production capacity of 400 million doses.
The Shenzhen drugmaker signed a deal with AstraZeneca in August 2020 to introduce the latter's COVID-19 vaccine into China for which it is seeking clinical registration.
The company itself developed an inactivated coronavirus vaccine and is planning to launch phase 3 trials.
China-made 'unmanned flying truck' HH-200 completes maiden flight
2026-04-16
China removes tens of thousands of 'AI-modified' videos in content crackdown
2026-04-10
What is space computing, and why move computing power into orbit?
2026-04-06
Hainan FTP draws more than 700 foreign firms 100 days after customs launch
2026-03-28
Announcement on the Global Open Recruitment for the Director (Legal Representative) of the Sanya Tourism Board
2026-03-21
Viral Chongqing nightscape video wows viewers with vision of China's urban future
2026-03-18
Chinese lawmakers approve 2026 central budget
2026-03-12
China's GDP to grow by over 6 trillion yuan this year
2026-03-07